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Endometrial	cancer	is	recognized	worldwide	as	one	
of	the	most	common	oncological	disorders	of	the	female	
genital	tract.	At	present	this	disease	is	being	diagnosed	
in	70%	of	cases	at	stage	III–IV,	when	it	 is	already	quite	
difficult	to	find	an	effective	treatment.	Molecular	changes	
in	structure	of	several	genes	have	recently	been	reported	
to	 lead	to	endometrial	cancer	progression.	Up	to	83%	
of	hormone-dependent	endometrioid	carcinomas	are	
associated	with	 the	 loss-of-function	mutation	 in	 the	
tumor	suppressor	PTEN	gene	located	on	chromosome	
10.	Altered	PTEN	expression	is	considered	as	a	marker	
of	the	earliest	endometrial	precancers	and	good	survival	
prognosis,	while	methylation	of	its	promoter	is	associated	
with	late-stage	disease	[1,	2].	Some	data	suggest	that	
structural	alterations	in	p53,	p16,	K-ras,	as	well	as	Her2/
neu	overexpression	may	have	prognostic	value,	though	
without	relation	to	histological	type	and	stage	[3–8].	Pre-
dictive	significance	of	K-ras	mutations	may	depend	on	
age	at	disease	onset.	However,	contradictory	reports	and	
polygenic	nature	of	the	disease	do	not	allow	to	consider	
the	known	molecular	markers	quite	reliable.	Thus,	further	
detailed	investigation	of	genetic	components	related	to	
endometrial	cancer	progression	is	needed	to	identify	ad-
ditional	molecular	markers	of	clinical	significance.	
For	this	purpose	we	conducted	our	study	in	two	direc-
tions:	1.	Detection	of	molecular	polymorphisms	in	micro-
satellite	loci	adjacent	to	the	known	E2F1,	BAX,	TCF7L2,	
C-MYC,	WNT1,	FES,	DCC,	P27,	THRA,	APC,	CYP19,	P53	
genes	and	estimation	of	their	association	with	endome-
trial	cancer	risk.	2.	Search	for	the	potential	molecular	
markers	in	anonymous	DNA	sequences	located	between	
microsatellite	 repeats	 (inter	simple	sequence	repeat	
polymorphism)	 in	human	genome,	sequence	analysis	
of	polymorphic	fragments,	their	identification	in	human	
genome	database	and	evaluation	of	their	possible	role	
in	endometrial	cancer	progression.
Materials and Methods
The	study	cohort	was	comprised	of	twenty	women	
with	surgically	and	histologically	confirmed	endome-
trial	cancer	who	underwent	surgery	at	the	Gynecology	
Clinic	of	Odessa	State	Medical	University,	Odessa,	
Ukraine.	All	subjects	were	informed	and	gave	written	
consent	to	participate	in	the	study	and	to	allow	their	
biological	 samples	 to	be	genetically	analyzed.	Ap-
proval	for	this	study	was	obtained	from	the	Scientific	
Council	of	Odessa	State	Medical	University.
DNA	was	extracted	 from	 the	 tumor	and	normal	
endometrial	tissue	samples	of	the	same	patients	us-
ing	“DNA	purification	kit”	(Promega	Corporation,	USA)	
according	 to	 the	manufacturer’s	 recommendations.	
DNA	was	stored	at	4	°C	until	analyzed.
The	amplification	of	12	microsatellite	loci	adjacent	
to	 the	known	E2F1, BAX, TCF7L2, C-MYC, WNT1, 
FES, DCC, P27, THRA, APC, CYP19, P53	genes	was	
performed.	The	primers	and	PCR	conditions	are	sum-
marized	in	Table	1.	
Four	 ISSR	primers	were	used	 to	discover	 new	
potential	DNA	markers:	ISSR1	—	(GTG)7A,	ISSR12	—	
(TG)9C,	 ISSR14	—	 (AC)9G,	 ISSR17	—	 (CA)10G.	
The	primers	were	synthesized	by	the	MWG-BIOTECH	
(Germany).	PCR	mix	 in	a	volume	of	25	μl	contained	
50	mМ	KCl,	20	mМ	Tris-HCl	(рН	8.4	at	25	°С),	MgCl2	
(2	mM	for	ISSR-primers	and	4	mM	for	SSR-primers),	
0.01%	Tween-20,	0.15	mМ	each	dNTP,	0.2	μМ	primers,	
10-20	ng	DNA,	0.8-1	U	Taq-polimerase.	
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Table 1. The primer sets and PCR conditions
Primer Sequence Annealing ( °C, s)
E2F1-f
E2F1-r
5�-TGCAGAAGTGGCCTTAGCAA-3�
5�-ATCATTGAACGAACAGGGGG-3�
58, 30
BAX-f 
BAX-r
5�-GCTCACTTTCACTGAGGATGC-3�
5�-TTAGGCCTAGCAGAGAATCACC-3�
50, 30
TCF7L2-f 
TCF7L2-r
5�-AGTGTGACTCTGGCCAAGCT-3�
5�-TGCTCTTTAAGGCACTCTTGC-3�
60, 30
C-MYC-f 
C-MYC-r
5�-CGTTAGAAAGGTCTCTGGAC-3�
5�-GTCTTAGGTAAGAATTGGCA-3�
56, 30
WNT1-f 
WNT1-r
5�-AGCTCTCACACACTCTCCTTCC-3�
5�-GGAAAGTTAAAGAGGCATCCG-3�
58, 30
FES-f
FES-r
5�-GCTTGTTAATTCATGTAGGGAAGGC-3�
5�-GTAGTCCCAGTCACTTGGCTACTC-3�
55, 30
DCC-f 
DCC-r 
5�-GATGACATTTTCCCTCTAGA-3�  
5�-TTTAGTGGTTATTGCCTTGAA-3�
56, 30
P27-f
P27-r
5�-GGCACTTCCCAGCATGTAGCCG-3�
5�-GTGGCCACATGGAGTGACCTGGGCCTC-3�
60, 30
THRA-f
THRA-r
5�-CTGCGCTTTGCACTATTGGG-3�
5�-CGGGCAGCGTAGCATTGCCT-3�
60, 30
APC-f 
APC-r 
5�-AGCAGATAAGACAGTATTGCTAGTT-3�
5�-ACTCACTCTAGTGATAAATCGGG-3�
50, 30
CYP19-f 
CYP19-r 
5�-ACAGGCAAGTGGCTGAGG -3�
5�-ATTCAGCATTGACCCTTGC-3�
58, 30
P53-f
P53-r
5�-AGGGATACTATTCAGCCCGAGGTG-3�
5�-ACTGCCACTCCTTGCCCCATTC-3�
58, 30
After	the	amplification	the	SSR-PCR	products	were	
analyzed	by	gel	electrophoresis	on	10%	polyacrilamide	
gels	under	denaturation	conditions,	 the	 ISSR-PCR	
products	—	on	6%	plolyacrilamide	gels.	Molecular	
weight	of	the	PCR	products	was	calculated	with	“Oned-
scan”	software	using	pUC18/MspI	as	a	standard.
Polymorphic	DNA	fragments	were	eluted	from	gel	
and	 reamplified	with	M13-tailed	primer	5�-TGT	AAA	
ACG	ACG	GGC	CAG	T-ISSR17–(CA)10G	 to	generate	
products	 for	sequencing.	PCR	was	carried	out	 in	a	
total	volume	of	10	μl	containing	20–50	ng	of	genomic	
DNA,	4–6	pmol	primer,	200	μM	dNTPs,	50	mM	KCl,	
2.5	mM	MgCl2;	10	mM	Tris-HCl	(pH	8.3),	1.5%	DMSO,	
50	mM	TMAC,	and	0.2	U	Tfi-polymerase.	Quality	of	the	
PCR-products	was	analysed	in	1%	agarose	gel.	The	
intensive	major	bands	were	cut	out	of	the	gel,	purified	
with	a	GFXTM	PCR	DNA	and	Gel	Band	Purification	
Kit	 (Amersham	Pharmacia	Biotech)	and	applied	 to	
direct	DNA	sequencing.	 The	 sequencing	 reaction	
was	performed	with	M13	primer	and	a	ThermoSe-
quenase	7-deaza-dGTP	Sequencing	Kit	(Amersham	
Pharmacia	Biotech)	using	 the	BioRad	 ICycler.	The	
process	included	20	cycles	of	30	s	at	95	°C,	30	s	at	
54	°C	and	1	min	at	72	°C.	The	products	were	resolved	
on	25	cm	7%	denaturing	Long	Ranger	gels	run	on	a	
Li-Cor	4000	sequencer,	following	the	loading	proto-
cols.	Sequences	were	base-called	using	 the	Base	
ImagIRTM	4.0	 (LI-COR)	software.	Sequence	homol-
ogy	was	determined	using	 the	NCBI	Blast	Software	
(http://www.ncbi.nlm.nih.gov).
resUlts
DNA	fragments	of	12	microsatellite	loci	were	ampli-
fied	with	primers	and	under	conditions	listed	in	Table	1.	
No	polymorphism	was	detected	for	10	of	them	at	com-
parison	of	different	genotypes,	or	different	samples	
from	the	same	patient	(tumor	versus	normal	tissue).	
Genotypic	differences	were	discovered	for	 the	DCC	
(170–170,	170–200,	195–195,	195–200	bp	genotypic	
variants)	and	FES	 (240–240,	240–244,	244–244	bp	
genotypic	variants)	loci.	However,	the	fragments	from	
different	samples	of	the	same	genotypes	did	not	differ	
in	their	pattern	with	the	only	exception:	in	one	genotype	
a	200	bp	fragment	was	absent	in	normal	tissue,	but	
present	in	cancer	sample.
In	this	study	we	also	performed	amplification	of	DNA	
fragments	with	4	ISSR-primers.	The	ISSR17–(CA)10G	
generated	100	bp	and	174	bp	polymorphic	fragments	
(Figure).	Polymorphic	100	bp	DNA	fragment	was	de-
tected	in	twelve	patients	(60%).	In	two	of	them	it	was	
absent	in	cancer	samples,	in	the	rest	of	the	patients	it	
was	present	both	in	cancer	and	normal	tissue	samples.	
Polymorphic	fragment	of	174	bp	in	length	was	detected	
in	seven	patients	(35%).	In	four	of	them	it	was	identi-
fied	only	in	normal	tissue	samples,	in	one	patient	–	in	
both	sample	types,	and	in	two	patients	–	only	in	cancer	
samples.	We	performed	sequencing	of	both	fragments	
and	checked	their	homology	to	the	known	genes	using	
human	genome	database.	The	analysis	included	only	
sequences	with	known	functions;	cloned	sequences	
or	sequences	with	supposed	functions	were	ignored.	
Sequences	homologous	to	100	bp	and	174	bp	frag-
ments	were	detected,	 correspondingly,	within	 the	
NFKB1	and	DDR1	genes	(Table	2).
figure. Products	of	DNA	amplification	by	ISSR17	(CA)	10G	pri-
mer.	C	—	tumor	sample,	N	—	normal	tissue	sample,	M	—	molecu-
lar	weight	marker	pUC18/MspI.	100	bp	and	174	bp	polymorphic	
DNA	fragments	are	indicated	by	arrows
discUssion
Microsatellites	are	short,	simple	repeated	sequenc-
es	of	DNA	distributed	throughout	the	human	genome.	
The	accumulation	of	insertion	or	deletion	mutations	in	
these	repetitive	sequences	results	in	a	form	of	genomic	
instability,	called	microsatellite	 instability	(MSI).	The	
MSI	has	been	reported	in	a	variety	of	both	hereditary	
and	sporadic	tumors,	 including	endometrial	cancer,	
and	has	been	shown	to	have	prognostic	significance	
[9].	However,	in	the	present	study	we	failed	to	detect	
significant	variability	for	microsatellite	loci	adjacent	to	
the	E2F1,	BAX,	TCF7L2,	C-MYC,	WNT1,	P27,	THRA,	
APC,	CYP19,	P53	genes	in	cancer	and	normal	tissue	
samples	obtained	 from	 the	endometrial	cancer	pa-
tients.	Genotypic	differences	were	detected	only	for	
the	loci	located	next	to	the	DCC	and	FES	genes,	but	
fragments	from	normal	and	cancer	tissue	samples	of	
the	same	genotypes	did	not	differ	in	their	pattern.	Of	
note,	DCC	regulates	normal	endometrial	cell	growth	
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and	is	recognized	as	the	tumor	suppressor	gene	for	
endometrial	cancer	[10].
In	our	previous	study	[11]	we	compared	the	vari-
ability	of	 the	above-mentioned	 loci	 in	patients	with	
leiomyoma,	a	benign	neoplasm,	using	 the	normal	
myometrium	as	a	control	 tissue.	According	 to	our	
observations,	detected	polymorphism	reached	40%	
at	 the	genotypic	 level,	and	up	 to	60%	 in	neoplastic	
and	normal	 tissue	within	 the	 same	genotype.	The	
SSR-markers	are	 far	 less	 informative	 in	 the	present	
study,	which	may	be	explained	by	differences	in	ge-
netic	pathways	involved	in	leiomyoma	and	endome-
trial	cancer	progression.	On	the	basis	of	our	data,	we	
conclude	that	the	analyzed	microsatellite	loci	adjacent	
to	 the	DCC	 and	FES	genes	cannot	be	 regarded	as	
markers	of	endometrial	cancer.	
Search	for	the	potential	markers	for	endometrial	
cancer	 in	anonymous	DNA	sequences	 located	be-
tween	microsatellite	 repeats	 revealed	100	bp	and	
174	bp	fragments.	The	first	fragment	detected	in	60%	
of	patients	appeared	to	be	homologous	to	a	sequence	
within	 the	NFKB1	gene.	NFKB1	 is	one	of	 the	genes	
controlling	 immune	response;	 loss	of	 its	expression	
suppresses	the	immune	system	and	apoptosis,	dis-
rupts	the	regulation	of	the	genes	involved	in	cell-to-cell	
interaction,	intercellular	communication	and	spreading	
of	primary	pathogenic	signals	[12].	Thus,	mutation	just	
in	one	NFKB1	gene	may	trigger	a	set	of	pathological	
processes	leading	to	tumor	formation.	The	discovered	
polymorphic	fragment	was	lost	in	two	cancer	samples,	
which	means	that	such	a	loss	may	affect	gene	function.	
Although	in	ten	patients	this	fragment	was	detected	
both	in	cancer	and	normal	tissue	sample,	it	has	to	be	
mentioned	that	we	did	not	perform	microdissection	in	
the	present	study,	so	DNA	derived	from	tumor	samples	
could	in	fact	contain	some	DNA	from	non-malignant	
cells.	The	presence	of	this	fragment	both	in	tumor	and	
normal	tissue	samples	of	some	patients	may	partly	be	
explained	by	such	DNA	heterogenity.
	Based	on	the	role	of	NFKB1	in	tumorigenesis	[12]	
and	our	own	observation,	we	conclude	that	the	NFKB1	
gene	may	be	 regarded	as	 a	 potential	 informative	
marker	for	endometrial	cancer	progression.	However,	
a	more	detailed	study	of	its	role	in	tumorigenesis	must	
be	performed	in	a	bigger	population	of	cancer	patients	
with	the	use	of	microdissection.
Another	polymorphic	fragment	of	174	bp	in	length,	
detected	in	35%	of	patients,	appeared	to	be	homolo-
gous	to	a	sequence	within	the	DDR1	gene.	It	is	known	
that	DDR1	is	overexpessed	in	some	human	tumors,	
e.	g.	breast,	ovarian,	esophageal	and	brain	tumors	
[13–15].	As	far	as	we	know,	no	data	concerning	its	
involvement	in	endometrial	cancer	progression	have	
been	published	previously.	However,	 evidence	 for	
its	activity	in	epithelial	cells	indirectly	confirms	such	
suggestion.	Besides,	 it	 plays	a	 key	 role	 in	 regula-
tion	of	cellular	growth,	differentiation,	metabolism,	
intercellular	communications	and	interaction	of	cells	
with	their	environment.	Suggestion	about	relation	of	
functional	 alterations	 in	 such	a	key	gene	 to	endo-
metrial	 cancer	progression	needs	 to	be	confirmed	
in	a	more	detailed	study.	The	results	presented	here	
show	that	the	polymorphic	fragment	may	be	present	
not	only	in	cancer	samples,	but	also	in	normal	tissue.	
Absence	of	regularities	in	the	populational	distribu-
tion	of	these	fragments	restricts	to	some	extent	the	
possibility	of	the	wide	application	of	such	markers.	On	
the	other	hand,	polymorphism	within	the	same	geno-
type	reflects	the	specific	ways	of	cancer	progression.	
Investigation	of	such	ways	will	tailor	modern	clinical	
medicine	to	each	patient	according	to	his/her	genetic	
fingerprints	and	drive	state-of-the-art	screening	and	
prevention	of	different	cancer	forms	to	a	new	level.	
On	 the	basis	of	our	observations	we	suggest	 that	
DDR1	may	 influence	 to	 some	extent	 endometrial	
cancer	development,	though	its	effect	may	depend	
on	genotype	and/or	stage	of	the	disease.
In	conclusion,	polymorphic	100	bp	and	174	bp	
DNA	fragments,	which	may	be	regarded	as	potential	
markers	of	endometrial	cancer,	were	detected	in	our	
study.		DNA	sequence	analysis	revealed	their	homol-
ogy	to	sequences	within	the	NFKB1	and	DDR1	genes.	
This	a	first	report	on	possible	association	of	NFKB1	
and	DDR1	with	endometrial	cancer.	The	pattern	of	
populational	distribution	of	discovered	polymorphic	
fragments	indicates	that	NFKB1	and	DDR1	may	be	
involved	 in	some	specific	pathways	of	endometrial	
cancer	development,	but	 their	 likely	 role	 in	patho-
logical	processes	demands	further	investigation	in	a	
more	detailed	study	using	microdissection.
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Table 2. Identified polymorphic DNA fragments and functions of corresponding genes (from Human Genome Database)
Polymorphic fragment 100 b.p. gggaggcagaggttgcagtgagccgagatcataccattgcactccag cctgggcaacagcagcgaaactccgtctcaaaaaataaataaaatatctgtgtgt-gtgtgtgtgtgtg (primer)
Gene Locus Function
Homo sapiens nuclear factor of 
kappa light polypeptide gene en-
hancer in B-cells 1 (NFKB1)
NT_011786 Regulation of the genes involved in cell-to-cell interaction, intercellular communication, cell recruitment 
or transmigration, amplification or spreading of primary pathogenic signals, and initiation or acceleration 
of tumorigenesis. 
Regulation of the immune system and programmed cell death [12]
Polymorfic fragment 174 b.p. ccagatggactcctgtcttacaccgcccctgtggggcagacaatgtatttatctgaggсcgtgtacctcaacgactccacctatgacggacataccgtgggcggg-
taagaaaggcccctgcaggatatggagtttggggtgggagggaggactctgtgtgtgtgtgtgtgtgtg (primer)
Homo sapiens discoidin domain 
receptor family, member 1 (DDR1)
NM_013993 Plays a key role in the communication of cells with their microenvironment. Regulation of cell growth, dif-
ferentiation and metabolism.
Plays a role in cell-to-cell contact and in cell adhesion signaling pathways [13–15]
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ИДЕНТИФИКАЦИЯ НОВЫХ МАРКЕРОВ РАКА ЭНДОМЕТРИЯ 
В гРуппЕ пАЦИЕНТОВ Из уКРАИНСКОЙ пОпуЛЯЦИИ
Цель: идентификация клинически значимых маркеров рака эндометрия. Материалы и Методы: проведен анализ 
SSR- и ISSR-полиморфизма в образцах опухолей и непораженной ткани эндометрия двадцати пациентов, получавших 
лечение в клинике гинекологии Одесского государственного медицинского университета (Одесса, Украина). Выполнено 
секвенирование выявленных полиморфных фрагментов ДНК, локализованных в анонимных участках генома между 
микросателлитными повторами (ISSR-полиморфизм), осуществлен анализ их гомологии с известными участками ДНК из 
базы данных генома человека. Результаты: не установлено значительной вариабельности микросателлитных повторов, 
соседствующих с генами E2F1, BAX, TCF7L2, C-MYC, WNT1, FES, DCC, P27, THRA, APC, CYP19 и P53. В процессе поиска 
новых маркеров рака эндометрия среди анонимных последовательностей ДНК, локализующихся между микросателлитными 
повторами, выявлены полиморфные фрагменты длиной 100 и 174 пн. Эти фрагменты присутствовали соответственно у 60 и 
35% пациентов  . Фрагмент длиной 100 пн оказался гомологичным участку гена NFKB1, а фрагмент длиной 174 пн – участку 
гена DDR1. Выводы: гены NFKB1 и DDR1 могут рассматриваться в качестве потенциальных маркеров некоторых типов 
рака эндометрия. Это первое сообщение о возможной ассоциации данных генов с опухолями эндометрия.
Ключевые слова: SSR-маркер, ISSR-маркер, рак эндометрия, секвенирование.
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